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Abstract
Adenosine reduces both evoked and spontaneous calcium-dependent acetylcholine (ACh) release through a mechanism
downstream of calcium entry at amphibian motor nerve endings (Silinsky EM. J Physiol 1984; 346: 243Y56). LY 294002
(2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one), an inhibitor of both phosphoinositide-3 kinase (PI-3 kinase) and
casein kinase II, has been reported to increase spontaneous ACh release reﬂected in miniature endplate potential (MEPP)
frequencies independently of intraterminal calcium at the frog neuromuscular junction (Rizzoli SO, Betz WJ. J Neurosci
2002; 22: 10680Y9). It has been suggested that the increase in MEPP frequency caused by LY 294002, is mediated
through an action on synaptotagmins, vesicle associated calcium sensors believed to trigger synaptic vesicle exocytosis.
We thus examined the effects of adenosine on MEPP frequencies and evoked ACh release reﬂected as endplate potentials
(EPPs) in order to determine if the presumed calcium-independent ACh release is affected by adenosine. We also wanted
to determine if PI-3 kinase or casein kinase II is involved in mediating or modulating the inhibitory effects of adenosine.
To these ends, we examined the effects of adenosine in the presence of LY 294002, wortmannin (a highly selective the
PI-3 kinase inhibitor), or DRB (5,6-dichlorobenzimidazole riboside, an inhibitor of casein kinase II). LY 294002 reduced
the sensitivity of both MEPP frequencies and the nerve-evoked calcium dependent EPPs to adenosine. The occlusive
effects of LY 294002 on the actions of adenosine on MEPPs and EPPs were overcome by increasing adenosine
concentration. Neither wortmannin nor DRB had any effect on the sensitivity of the EPPs to adenosine indicating that
neither PI-3 kinase nor casein kinase II inhibition mediates the reduction in motor-nerve terminal sensitivity to adenosine
produced by LY 294002. The results indicate a competitive relationship between LY 294002 and adenosine at A1
receptors at the frog neuromuscular junction. This effect is independent of the previously described effects of LY 294002
on the exocytotic process, and is also independent of PI-3 kinase or casein kinase II.
Abbreviations: ACh – acetylcholine; DRB–5,6-dichlorobenzimidazole riboside; EPPs–end-plate potentials; LY 294002–
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; MEPPs–miniature end-plate potentials; PI-3 kinase–phosphoinosi-
tide-3 kinase
Introduction
Activation of A1 receptors by adenosine is known to inhibit
the release of acetylcholine (ACh) from frog motor nerve
terminals through a mechanism that occurs downstream of
calcium entry [1Y4]. In the frog, the effects of the acti-
vation of A1 receptors by adenosine on both the sponta-
neous MEPPs and nerve-evoked EPPs are comparable,
with the maximal inhibition for both classes of events
being in the order of 50% [2, 5, 6]. The rapid timing and
stimulus independence of this inhibition indicates that
adenosine must act on vesicles which are in a post-primed
fully release-competent state [7, 8]. Thus, the most likely
candidates for mediating the inhibition of transmitter
release by A1 receptor activation at the frog neuromuscular
junction are the core components of the exocytosis
machinery i.e., the SNARE proteins (SNAP-25, syntaxin
and synaptobrevin), the calcium sensor synaptotagmin or a
thus far uncharacterised element of the secretory apparatus.
On the basis of biophysical evidence it was previously
suggested that inhibition of ACh release by adenosine
occurs through an action on the calcium sensor responsible
for triggering release [1, 7]. More recently we found
further evidence for this suggestion [9] using the com-
pound 4-aminoquinaldine. In brief we found that, at the
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naldine induces the appearance of a population of calcium
insensitive giant size MEPPs, quantal synaptic events that
are independent of a functional calcium sensor [9]. In
addition to the lack of sensitivity to calcium, these events
are not affected by adenosine, leading us to conclude that a
functional form of synaptotagmin is necessary for mediat-
ing the actions of adenosine on transmitter release at the
frog neuromuscular junction.
Given the apparent importance of synaptotagmin in me-
diating the inhibition of release of acetylcholine by aden-
osine, and of PI-3 kinase and casein kinase in modulating
the secretory apparatus [10], it seems possible that agents
that alter synaptotagmin function or these two kinases
might also affect the action of adenosine at motor nerve
endings. Work by Rizzoli and Betz [10] suggests that 2-
(4-morpholinyl)-8-phenyl-4H-1-Benzopyran-4-one (LY
294002) an inhibitor of both phosphoinositide-3 kinase
and casein kinase II is a promising candidate for these
experiments. As reported by these coworkers, application
of LY 294002 causes a substantial acceleration of MEPP
frequency at the frog neuromuscular junction, through a
mechanism that is independent of intraterminal calcium
[10]. As a result Rizzoli and Betz proposed that LY 294002
causes the release of MEPPs through a perturbation of
synaptotagmin function.
The aim of this work was thus twofold. Firstly, we
wished to determine whether MEPPs released as a result of
this proposed perturbation of synaptotagmin function by
LY 294002 are subject to the same regulation by adenosine
as normal calcium-dependent release at the frog neuro-
muscular junction. Secondly we wished to determine if any
effects of LY 294002 on the action of adenosine is me-
diated by PI-3-kinase or casein kinase II.
Materials and methods
General
Frogs (Rana pipiens) were killed by anaesthesia with 5%
ether, followed by double pithing, in accordance with
guidelines laid down by our institutional animal welfare
committee. Isolated cutaneous-pectoris nerve-muscle prep-
arations were used in all experiments. Intracellular record-
ings were made using microelectrodes ﬁlled with 3 M KCl
with resistances 3Y10 MW. The signal from the microelec-
trode was fed into a conventional high-input impedance
microelectrode pre-ampliﬁer (Axoclamp-2A, Axon Instru-
ments), the signal was then passed from the axoclamp
through an AC coupled ﬁlter with a 10 KHz low pass ﬁlter.
Responses were fed into a personal computer using a
Digidata 1200 (Axon Instruments) and digitized at a 0.1 ms
sampling rate. Solutions were delivered by superfusion
with a peristaltic pump and removed by vacuum suction. In
the experiments on the effects of adenosine and 2-chloro-
adenosine on EPPs recorded in the presence of either LY
294002 or wortmannin, EPPs were evoked at 0.02 Hz, in
order to minimize the rate of EPP run-down. In addition,
solution exchange was maximized with a 5 ml/min super-
fusion rate of the 1.5 ml recording chamber. Lastly, in
order to have the maximal accuracy for these experimental
results, a maximum of three concentrations of adenosine
was tested between washes in the LY 294002 experiments.
When necessary, corrections to the EPP amplitudes were
made assuming a linear rundown rate (see inset to Figure 3).
All experiments were carried out at room temperature
(22Y24 -C).
Normal recording solutions contained (mM): NaCl, 115;
KCl, 2; HEPES, 2; and CaCl2, 1.8 mM. Records of MEPPs
were made (418.5 s recording duration) and analysed using
CDR and SCAN programs (DOS versions, Strathclyde
University Value-Packed Software; John Dempster). In
experiments where the effects of drugs on the endplate
potentials (EPPs) was determined, preparations were
paralyzed with 10 mM (+)-tubocurarine. EPPs were evoked
by stimulation of the nerve at low frequencies (0.02 Hz).
Statistical methods
Data are presented as the mean T S.E.M. In most cases, the
data groups were ﬁrst tested for normality and then tested
for signiﬁcance using one-way analysis of variance (Sigma
Stat, Jandel Scientiﬁc Inc). A Student’s t-test was then used
to compare individual groups. Differences between groups
were considered signiﬁcant when P G 0.05, but in some
cases further statistical details are provided. Unless
otherwise stated, n represents the number of single experi-
ments carried out at single end-plates.
Drugs
LY 294002 and wortmannin were purchased from Tocris
Bioscience, Ellisville, USA. Adenosine, 2-chloroadenosine
and DBR were purchased from Sigma St Louis, USA.
Results
LY 294002-evoked MEPPS and the effects of adenosine
In our initial experiments we found that the application of
LY 294002 (150 mM) produced a 3.5 fold increase in
MEPP frequency similar to that previously described by
Rizzoli and Betz [10]. Speciﬁcally, in control conditions,
MEPP frequencies were 0.8 T 0.2 Hz; following applica-
tion of 150 mM LY 294002, MEPP frequencies increased
to 3.5 T 0.9 Hz (n =5 ,P G 0.05).
We next compared the effects of adenosine on normal
MEPPs and on MEPPs evoked by LY 294002. In control
experiments, 25 mM adenosine produced a 51 + 3.8%
(n = 4) reduction in MEPPs. This is a similar to the max-
imal inhibition by adenosine previously reported for
MEPPs [6]. In contrast, 25 mM adenosine had no signi-
ﬁcant (P > 0.05) effect on MEPPs evoked by LY 294002.
In Figure 1, which depicts a typical experiemtal result, the
control MEPP frequency (Figure 1a) was 3.9 s
j1 T 0.1 s
j1
(mean + 1 S.E.M.) and following application of adenosine
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Figure 2, which shows the average results from ﬁve
experiments, also illustrates that the inhibitory effect of
LY 294002 was surmountable. Speciﬁcally, LY 294002
obtunds the inhibitory effects of adenosine (black bar)
when compared to control (open bar) yet increasing the
concentration of adenosine to 200 mM produced the same
level of inhibition of LY 294002-induced MEPPs (grey
bars) as that produced by 25 mM adenosine on normal
MEPPs (for further statistical details, see Figure legend).
These results support the suggestion that alteration of
synaptotagmin function by LY 294002 might reduce the
potency of adenosine as an inhibitor of spontaneous ACh
release at the frog neuromuscular junction.
The effect of LY 294002 on the inhibition of EPPs
by adenosine
In order to investigate whether the failure of 25 mM
adenosine to decrease MEPP frequency relates to the
calcium independence of LY 294002-evoked MEPPs, ex-
periments were then carried out on the effects of adenosine
on evoked ACh release (i.e., EPPs) in the presence and
absence of LY 294002. If the reduced potency of adenosine
is due to the calcium insensitive of the LY 294002 MEPPs,
then the 25 mM adenosine should have its usual inhibitory
effect on EPPs in the presence of LY294002 as evoked ACh
release is calcium-dependent.
As previously found [10], LY 294002 caused an im-
mediate initial increase in EPP amplitudes followed by a
slower incremental reduction in EPP amplitudes (see
Figure 3). The reduction in EPP amplitudes is attributable
to the known inhibition by LY 294002 of PI-3 kinase (an
enzyme which is known to play a crucial role in recycling
vesicles for re-release Y see [10Y12]). Our adenosine
concentration response experiments were thus carried out
towards the end of this second phase in the action of
LY 294002, where the EPP amplitudes are only declining
very slowly (see inset to Figure 3). In order to minimize the
rate of run-down, EPPs were evoked at 0.02 Hz. As shown
in Figure 4a, adenosine also had a reduced potency and
efﬁcacy on EPPs in the presence of LY 294002 (150 mM,
ﬁlled squares) when compared with control (open circles).
It thus appears that calcium-dependent and calcium inde-
pendent ACh release both have the same reduced sensitiv-
ity to adenosine in the presence of LY 294002.
The effect of LY 294002 on the inhibition of EPPs
by 2-chloroadenosine
It could be argued that the reduction in the potency of
adenosine might be a result of modiﬁcations in the ac-
tivities of nucleoside transporters, adenosine deaminase,
adenosine kinase, or another mechanism involved in the
elimination of adenosine. While this suggestion seemed
unlikely, given the degree of the reduction in the potency
of adenosine seen, we could not entirely rule it out. The
selective A1 receptor agonist 2-chloroadenosine is not a
substrate for either deamination or uptake [2]. We therefore
tested the effects of 150 mM LY 294002 on the action of
2-chloroadenosine with a partial dose response curve. As
shown in Figure 4b, LY 294002 produced a reduction in
the potency of 2-chloroadenosine (ﬁlled squares) from the
control level (open circles) that is comparable to the re-
duction in the potency of adenosine (Figure 4a).
Figure 1. The effect of adenosine (25 mM) is greatly obtunded in the
presence of LY 294002 (150 mM). (A) shows control MEPPs generated by
LY 294002 and (B) shows the effects of adenosine on these MEPPs.
MEPP frequency in LY 294002 alone was 3.9 s
j1 T 0.1 s
j1 (mean + 1
S.E.M.), following application of adenosine (25 mM), MEPP frequency
was 3.6 T 0.1 s
j1 (B). This is in contrast to the approximately 50%
inhibition produced by adenosine in the absence of LY 294002 [2]. The
membrane potential in this experiment was j67 mV throughout.
Figure 2. The effect of adenosine on MEPP frequencies recorded in
the absence and the presence of 150 mM LY 294002. In the absence of
LY 294002, 25 mM adenosine reduced MEPP frequencies to 51 T 3.8%;
n =4 ,( P G 0.05) of that recorded in the absence of adenosine (open
bar; 100% = 1.1 Hz). In the presence of 150 mM LY 294002 MEPP
frequencies were not signiﬁcantly reduced by 25 mM adenosine (84.9 T
5.9%; n = 5, of that recorded in the absence of adenosine, black bars;
100% = 2.7 s
j1). The effect was surmountable by increasing the con-
centration of adenosine to 200 mM j52.3 T 7.2%; n =5 ,( P G 0.05, grey
bar; 100% = 4.3 s
j1).
LY294002 inhibits adenosine receptor activation 391The similar inhibition by LY 294002 of the action of aden-
osine on presumed synaptogtagmin-independent MEPPs and
on calcium and synaptotagmin-dependent EPPs suggests that
the LY 294002-adenosine interaction is unrelated to a selec-
tive perturbation of synaptotagmins. As LY 294002 inhibits
both PI-3 kinase and casein kinase II, we next wished to de-
termine if the reduction in sensitivity of the release process to
adenosinewasduetoinhibitionofeitherofthesetwoenzymes.
Figure 3. The effect of LY294002 (150 mM) on EPP amplitudes. The graph shown illustrates the effects of LY 294002 on EPPs in a single
representative cell. Each point plotted represents a single evoked EPP. As shown, following application of LY 294002 (150 mM), EPPs initially increased
in amplitude. After approximately 10 min following the initial application of LY 294002 EPPs began to rundown. Following 90 min in the presence of
LY 294002 the rate in rundown in EPP amplitudes was reduced such that the effects of adenosine could be tested (see arrows and inset). The membrane
potential was j103 mV throughout the course of this experiment.
Figure 4. The effect of the LY 294002 (150 mM) on the concentration-dependent inhibition of EPP amplitudes by adenosine (a) and 2-chloroadenosine
(b). As shown in (a), the potency of adenosine was signiﬁcantly reduced by the presence of 150 mM LY 294002. In control the concentration of
adenosine that produced a 50% inhibition of ACh release was 6.7 + 1.8 mM n = 4, in LY 294002 this concentration was 59.0 + 21.4 mM( n = 4). As
shown in (b), the potency of 2-chloroadenosine was signiﬁcantly reduced by the presence of 150 mM LY 294002. In control, threshold the concentration
of 2-chloroadensoine that reduced ACh release to 50% of the control level was 3.9 + 0.5 mM n = 4, in LY 294002 this value was 32.0 + 11.8 mM( n =4 ,
P G 0.05). These results suggest that the reduction in the potency of adenosine produced by LY 294002 at the frog neuromuscular junction is not
mediated by the upregulation of the endogenous mechanisms responsible for the elimination/degradation of adenosine by LY 294002. Each point on the
concentration response curves represents the average T SEM of n = 4 experiments.
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responsible for the reduced potency of adenosine?
We ﬁrst investigated the effects of the PI-3 kinase inhibitor
wortmannin (3 mM) on the adenosine dose response curve.
As previously described [11, 12], 3 mM wortmannin
produced a gradual stimulus dependent decline in EPP
amplitudes. This effect has been attributed to an impair-
ment of the PI-3 kinase dependent recycling process.
Inhibition of recycling is maximal with a concentration of
1 mM wortmannin [12]. However, the effectiveness of
adenosine as an inhibitor of evoked release was unchanged
(see Figure 5, ﬁlled circles).
We then investigated the effects of the casein kinase II
inhibitor 300 mM DRB [13] on the inhibition of ACh
release by adenosine. This concentration of DRB has been
previously shown to mimic the increase in MEPPs pro-
duced by LY 294002 [10]. It was previously shown that
300 mM DRB produced a ﬁve fold increase in MEPP fre-
quency [10] which is comparable with the 3Y4 fold in-
crease in MEPPs we found with 150 mM LY 294002.
However, as shown in Figure 5 (ﬁlled triangles), 300 mM
DRB had no effect on the inhibition of EPPs by adenosine.
These results suggest that the reduced potency of adenosine
in the presence of LY 294002 is not the result of either
inhibition of PI-3 kinase or inhibition of casein kinase II,
but rather through an action on adenosine receptor sig-
nalling cascade.
Discussion
In this study, we conﬁrmed previous ﬁndings that the ap-
plication of LY 294002 (150 mM) produced an increase in
MEPP frequencies. In addition, we found that there was a
reduced sensitivity of the motor nerve ending to adenosine
in the presence of this compound. This reduction in sensi-
tivity to adenosine was demonstrated in both the effects of
adenosine on MEPP frequencies and on evoked EPPs and
hence was not due to any selective effect of LY 294002 to
generate calcium independent ACh release through an inter-
action with casein kinase II [10]. Rather the results suggest
an apparent competitive relationship between A1 adenosine
receptor activation and LY 294002. This effect is unrelated
to inhibition of PI-3 kinase or casein kinase II as neither
the selective PI-3 kinase inhibitor, wortmannin, nor the
casein kinase inhibitor II, DRB, had any effect on the
sensitivity of nerve evoked EPPs to adenosine.
LY 294002 has been found to have a number of different
actions in a variety of systems. As well as its inhibitory
actions on PI-3 kinase and casein kinase II [14], it has been
reported to inhibit both DNA dependent kinase [15] and
the mammalian target of rapamycin (mTOR) [16]. In
addition, LY 294002 has been shown to increase intracel-
lular calcium in both bovine and human airway smooth
muscle [17]. With respect to interactions between LY
294002 and adenosine, it has previously been reported
in the hamster vas deferens smooth muscle cell line
DDT1MF-2, that LY 294002 (100 mM) blocks the phos-
phorylation of protein kinase B mediated by activation of
the A1 receptors [18]. In those experiments, wortmannin
(100 nM) also blocked the phosphorylation of protein
kinase B triggered by the A1 receptor agonist N
6-cyclo-
pentyladenosine, leading to the suggestion that A1 recep-
tors mediate phosphorylation of protein kinase B through a
PI-3 kinase dependent pathway in that system [18].
However, this mechanism does not seem likely at the frog
neuromuscular junction as both the speed at which A1
receptor activation inhibits transmitter release (G 100 ms
[19]), and the failure of wortmannin to affect the sensitivity
of evoked EPPs to adenosine, appears to preclude a role for
PI-3 kinase as the mechanism by which adenosine inhibits
transmitter release in this preparation.
It might be argued that the lack of effect of wortmannin
on the adenosine concentration response curve might be
due to a lower effectiveness of wortmannin against PI-3
kinase. However, the concentration of wortmannin we used
exceeds the concentration of wortmannin (30 nM) used in
the studies on the DDT1MF-2 cells. In addition, wortman-
nin produced a stimulation dependent decline in EPP
amplitude, an effect consistent with inhibition of PI-3
kinase [13, 14]. Thus, it seems unlikely that inhibition of
PI-3 kinase is responsible for the reduction in sensitivity to
adenosine produced by LY 294002 in this study. Similarly,
Figure 5. The effect of the PI-3 kinase inhibitor wortmannin (3 mM) and
the casein kinase II inhibitor DRB (300 mM) on the concentration depen-
dent inhibition of EPP amplitudes by adenosine. As shown, neither
wortmannin nor DRB had any signiﬁcant effect on the adenosine
concentration dependent inhibition of EPP amplitudes. Each point on the
concentration respose curves represents the average T SEM of n =4
experiments. The threshold concentration of adenosine that inhibited ACh
release to 50% of the control level in control experiments was 6.5 T 1.9
mM( n = 4). In the presence of wortmannin this value was 6.7 T 0.4 mM( n
= 4) and in the presence of DRB (300 mM) 9.4 + 1.9 (n = 4); (P 9 0.05).
LY294002 inhibits adenosine receptor activation 393the failure of the casein kinase inhibitor II, DRB, to alter
the sensitivity of adenosine actions on EPPs as is evi-
denced by the lack of effect on the adenosine concentration
response curves, makes it unlikely that inhibition of casein
kinase II activity by LY 294002 underlies the decrease in
effectiveness of adenosine. However, we acknowledge that
we did not directly measure the activity of either kinase in
these studies so we cannot entirely rule out a role for either
kinase in reducing the sensitivity of the motor nerve to
adenosine. The observation that the reduction in sensitivity
of the frog neuromuscular junction to adenosine can be
overcome by increasing adenosine concentration (both for
evoked release and for the release of the spontaneous
MEPPs) is consistent with there existing a competitive
relationship between adenosine and LY 294002 at the level
of the A1 receptor in this preparation. While we cannot
exclude an effect of LY 294002 at the level of the G-
protein, pertussis toxin progressively inactivates G-proteins
and occludes the inhibitory action of adenosine in a manner
that is not surmountable by increasing the concentration of
adenosine [20].
In conclusion, LY 294002 reduces the sensitivity of both
evoked and spontaneous release of ACh to the actions of
adenosine at the frog neuromuscular junction. It seems
likely that this action of LY 294002 is not due to its known
effects on either PI-3 kinase activity or on casein kinase II
nor due to its proposed actions on synaptotagmins, but
rather is mediated through a direct action on A1 receptors.
As a consequence of these ﬁndings, further caution needs
to be applied to the use of LY 294002 for studies of PI-3
kinase action, particularly in those systems where A1
receptor may play a role in cell signaling.
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